Metals E-Trading Catches Investor Frenzy in India

"Thousands of investors are flocking to the online spot commodities market."

India is emerging as one of the largest marketplace for trading in precious metals and base metals in the world. While investing in commodities and trading in futures market are attracting increasing participation across the country, a new form of commodities investment has sprouted up in India: E-trading in spot gold, silver, copper and other commodities.

Till now, buying gold, silver, copper or trading in any commodities has been through physical dealers or through futures exchanges. But these days, investor frenzy is catching up with E-trading in spot commodities in India.

India's only active commodities exchange for spot market—the National Spot Exchange Limited (NSEL)—offers E-Gold, E-Silver and E-Copper that are driving thousands of investors to trade in online spot commodities market.

NSEL is promoted by India's largest commodities exchange—the Multi Commodity Exchange (MXC). MCX is one of the leading global commodities exchanges in precious metals, base metals and energy.

According to Anjani Sinha, MD & CEO, NSEL, the investor response to the exchange e-series of spot commodities has been tremendous. "The overwhelming response received by e-Gold and e-Silver has convinced us about investment appetite for e-series products. e-Gold and e-Silver are distinguished by their simplicity, transparency, accessibility, affordability, tradability and cost effectiveness. Thus, it is value for money for investors, who are diversifying their portfolios through these products," says Sinha.

NSEL's has launched E-trading in several metals and agricultural commodities. The exchange's main products these days are E-Gold and E-Silver products that are posting record turnovers, owing to enhanced participation by retail investors. In terms of lots, daily trading in E-Gold takes place to the tune of nearly 200000 lots, while E-Silver has a turnover of around 250000 lots.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.